New Mexico Medicaid does not cover Wegovy or Zepbound for weight loss

New Mexico Medicaid, including Turquoise Care, does not cover Wegovy, Zepbound or Saxenda for weight loss: the Health Care Authority lists them as not covered. It covers some older weight-loss drugs, such as phentermine and orlistat, with prior authorization.12

New Mexico Medicaid does not cover Wegovy, Zepbound or Saxenda for weight loss, so there is no prior authorization path for them. The Health Care Authority's weight-loss prior authorization criteria apply only to the older weight-loss drugs it covers, such as phentermine and orlistat.12

• A BMI over 40, or a BMI of 35 or more with added risk factors (high blood pressure, diabetes or dyslipidemia).
• A six-month trial of calorie restriction and exercise is recommended but not required.
• Approval is for an initial three months; for Meridia and Xenical it can continue for a year with at least 3% body weight loss and improvement of related conditions.

Coverage for other uses the FDA has approved:

• Ozempic, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea and atherosclerotic heart disease: The Legislative Finance Committee lists these, with type 2 diabetes, as uses for which New Mexico Medicaid reimburses Ozempic and other GLP-1s; it does not name the drug for each use or the approval criteria.89
• Ozempic, child obesity under the early and periodic screening, diagnostic and treatment (EPSDT) benefit: The Legislative Finance Committee lists child obesity, under the EPSDT benefit, as a use for which New Mexico Medicaid reimburses Ozempic and other GLP-1s; we found no HCA document with the criteria.89

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Health Care Authority announcement that New Mexico has joined.10

State Health Benefits, which moved from the General Services Department to the Health Care Authority, uses Express Scripts as its pharmacy benefit manager for the July 1, 2026 to June 30, 2027 plan year. A Legislative Finance Committee brief says the plan started managing the use of weight-loss drugs more closely, but we found no public plan document that states its GLP-1 weight-loss rule.111213

Pharmacy benefit: Express Scripts (pharmacy benefit manager); BCBSNM, Presbyterian and UnitedHealthcare/UMR (medical).

Marketplace (ACA) plans: New Mexico's essential health benefits benchmark plan, in effect since plan year 2022, covers prescription drugs that are medically necessary to treat obesity and morbid obesity.16

The GLP-1 diabetes drugs are not one of the drug classes on the statewide Medicaid preferred drug list that took effect July 1, 2026, so each Turquoise Care plan and fee-for-service manage them on their own. Blue Cross and Blue Shield of New Mexico's Turquoise Care drug list covers Ozempic, Mounjaro and generic liraglutide (Victoza) with a required diagnosis and prior authorization.34567

In 2025, New Mexico Medicaid paid for 63,928 GLP-1 prescriptions, $64.1 million before rebates: 30 per 1,000 residents, against 32 across the states and DC, 19th of 51.63 It reimbursed 6 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 75 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.3839293025331828

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2526271833343536373231
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.202218

In 2024, Medicare Part D drug plans paid for 118,562 GLP-1 claims from prescribers in New Mexico, $147.0 million in total drug cost.64

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.68 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check New Mexico on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.6970 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by New Mexico’s board of pharmacy or attorney general on their own sites.

The FDA’s register lists 0 outsourcing facilities (503B) in New Mexico, as of November 6, 2026.65